Full Year Report 2016
2016 - First profitable year Fourth quarter 2016 · Total net revenues MSEK 184.7 (228.3) · Zubsolv® net revenue MSEK 128.2 (120.3) · Net earnings MSEK 33.3 (-51.8) · Earnings per share, before and after dilution, SEK 0.97/0.96 (-1.50) · Cash and cash equivalents MSEK 282.4 (198.1) · Together with Mundipharma Orexo made the first EU regulatory submission of a Marketing Authorisation Application (MAA) for Zubsolv for the treatment of opioid dependence · FDA approved a new unique low 0.7mg/0.18mg dosage of Zubsolv · The US District Court for the District of
